Foslinanib clinical trials
Also written CVM-1118 and TRX-818.
Includes 2 studies of Foslinanib disodium.
How each study uses foslinanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the foslinanib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
TaiRx, Inc. (7)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test foslinanib.
- Dec 2026CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaPhase 2 · TaiRx, Inc.
Studies
Open first, then newest update. How each study uses foslinanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCCRecruitingPhase 2TaiRx, Inc.NCT07521852Written as CVM-1118 + Sintilimab + TACE
- CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaRecruitingPhase 2TaiRx, Inc.NCT05257590Written as CVM-1118
- Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsActive, not recruitingPhase 2TaiRx, Inc.NCT03600233Written as CVM-1118
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular CarcinomaTerminatedPhase 2TaiRx, Inc.NCT03582618Written as CVM-1118
- Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer PatientsCompletedPhase 1TaiRx, Inc.NCT04336124Written as CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)
- A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced CancerCompletedPhase 1TaiRx, Inc.NCT02507544Written as TRX-818 capsules
- Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor PatientsCompletedPhase 1TaiRx, Inc.NCT02703298Written as TRX-818 capsules
Codes
What other systems call foslinanib · ClinicalTrials.gg INT014546
- UNII (FDA) 2X2DNM7NGXFOSLINANIBOne source FDA
- NCI Thesaurus C123824FoslinanibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2X2DNM7NGX | FOSLINANIB | One source FDA |
| NCI Thesaurus | C123824 | Foslinanib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.